Historically, crizotinib held precedence as the favored first-line treatment for ALK-positive NSCLC patients, as it demonstrated superior treatment responses, extended overall survival, and prolonged progression-free survival (Ou et al., 2020). Here, ALK is linked to non-small cell lung carcinoma.